To shed light on the specificity of the immune-related transcriptional programs activated in tumor cells by distinct classes of epigenetic drugs, we carried out a comparative profiling of gene signatures induced by DNMT, HDAC, BET and EZH2 inhibitors in the melanoma context, a tumor type currently treated by immunotherapy. The gene discussed is DNMT1; the disease is melanoma.